K. Aogi

1.1k citations

33 papers · 770 indexed · h-index 13

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
Cancer Research top 10%
- Breast Cancer Treatment Studies

Papers in ⓘ

Cancer Research 15
- Breast Cancer Treatment Studies 15
Oncology 27
- Cancer Treatment and Pharmacology 22
- HER2/EGFR in Cancer Research 13
- Colorectal Cancer Treatments and Studies 2

Co-authors: Hiroji Iwata (13 shared papers)Shigemitsu Takashima (3 shared papers)Norikazu Masuda (11 shared papers)Yasuhiro Fujiwara (6 shared papers)Yutaka Tokuda (4 shared papers)Yosuke Sasaki (2 shared papers)Yoshiaki Rai (2 shared papers)Noriyuki Katsumata (2 shared papers)
Journals: Annals of Oncology (10 papers)Journal of Clinical Oncology (8 papers)Cancer Research (6 papers)Japanese Journal of Clinical Oncology (2 papers)Breast Cancer Research and Treatment (2 papers)
Partner nations: Japan United States South Korea

In The Last Decade

K. Aogi

33 papers receiving 761 citations

Peers

Countries citing papers authored by K. Aogi

Since Specialization

Citations

This map shows the geographic impact of K. Aogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Aogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Aogi more than expected).

Fields of papers citing papers by K. Aogi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Aogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Aogi. The network helps show where K. Aogi may publish in the future.

Co-authors

The 25 scholars most cited alongside K. Aogi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with K. Aogi Line = papers co-authored together K. Aogi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer Annals of Oncology ·Kenji Tamura, Chikako Shimizu, Takashi Hojo, Sadako Akashi‐Tanaka, Takashi Kinoshita, Kan Yonemori, T. Kouno, Noriyuki Katsumata, Masashi Ando, K. Aogi, Fumiaki Koizumi, Kazuto Nishio, Yasuhiro Fujiwara	2010	139
2	Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry Annals of Oncology ·Naoki Niikura, Ai Tomotaki, Hiroaki Miyata, Takayuki Iwamoto, Masaaki Kawai, K. Anan, Naoki Hayashi, K. Aogi, Takashi Ishida, Hideji Masuoka, Kotaro Iijima, Shinobu Masuda, Koichiro Tsugawa, Takayuki Kinoshita, Seigo Nakamura, Yutaka Tokuda	2015	131
3	A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer Annals of Oncology ·K. Aogi, Hiroji Iwata, Norikazu Masuda, Hirofumi Mukai, Masayuki Yoshida, Yoshiaki Rai, Kenichi Taguchi, Yosuke Sasaki, Shigemitsu Takashima	2011	105
4	Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies British Journal of Cancer ·Masakazu Toi, Hiroji Iwata, Yasuhiro Fujiwara, Yoshiaki Ito, Shôji Nakamura, Yutaka Tokuda, Tetsuya Taguchi, Yoshiaki Rai, K. Aogi, T Arai, Junichiro Watanabe, T. Wakamatsu, Koichi Katsura, Catherine Ellis, Robert Gagnon, Kathleen Allen, Yosuke Sasaki, Shigemitsu Takashima	2009	68
5	Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. PubMed ·K. Aogi, K Kitahara, I Buley, Martin Bäckdahl, H Tahara, Takashi Sugino, (unknown), Steve Goodison	1998	58
6	Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802) Annals of Oncology ·Noriyuki Katsumata, Toru Watanabe, Hironobu Minami, K. Aogi, Toshio Tabei, Muneaki Sano, Norikazu Masuda, Jiro Andoh, Tadashi Ikeda, Taro Shibata, Shigemitsu Takashima	2009	34
7	Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients Japanese Journal of Clinical Oncology ·Daisuke Takabatake, Naruto Taira, Fumikata Hara, T. Sien, Sachiko Kiyoto, S Takashima, K. Aogi, Shozo Ohsumi, Hiroyoshi Doihara	2009	33
8	Telomerase activity in soft-tissue and bone sarcomas. PubMed ·K. Aogi, A Woodman, Virginia Urquidi, D. C. Mangham, (unknown), Steve Goodison	2000	33
9	A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy Annals of Oncology ·Yoshihiko Segawa, K. Aogi, Kenichi Inoue, Muneaki Sano, Ikuo Sekine, Yutaka Tokuda, Hiroshi Isobe, Takashi Ogura, Masahiro Tsuboi, Shinji Atagi	2009	27
10	Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) Cancer Research ·Masakazu Toi, SJ Lee, Eun‐So Lee, Shoichiro Ohtani, Y-H Im, S-A. Im, Byeong‐Woo Park, S-B. Kim, Y. Yanagita, Shintaro Takao, Shigeo Ohno, K. Aogi, Hiroji Iwata, A Kim, Hironobu Sasano, Isao Yokota, Yasuo Ohashi, Norikazu Masuda	2016	25
11	Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer Japanese Journal of Clinical Oncology ·Hiroshi Yamamoto, Masahiko Ando, K. Aogi, H. Iwata, Kenji Tamura, Kan Yonemori, Chikako Shimizu, Fumikata Hara, Daisuke Takabatake, Masaya Hattori, Tetsuya Asakawa, Yasuhiro Fujiwara	2014	21
12	Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC). Cancer Research ·Carlos H. Barrios, M. Liu, S. Lee, Laurence Vanlemmens, Jean-Marc Ferrero, Toshio Tabei, Xavier Pivot, Hiroji Iwata, K. Aogi, Marla Jo Brickman, K. Zhang, Kenneth A. Kern, María P. Martín	2009	15
13	Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey Breast Cancer Research and Treatment ·Kosuke Kawaguchi, Hiroshi Ishiguro, Satoshi Morita, Seigo Nakamura, Shinji Ohno, Norikazu Masuda, Hiroji Iwata, K. Aogi, Katsumasa Kuroi, Masakazu Toi	2011	13
14	Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari) Breast Cancer Research and Treatment ·Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, K. Aogi, K. Anan, (unknown), Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Motoko Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Shinji Ohno, Masakazu Toi	2017	10
15	A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) Annals of Oncology ·Hitomi Sakai, Junji Tsurutani, Yukinori Ozaki, Hiroshi Ishiguro, Kazuki Nozawa, Takashi Yamanaka, K. Aogi, Koji Matsumoto, T. Iwasa, Michio Tokiwa, Michiko Tsuneizumi, Y. Miyoshi, Chiyoe Kitagawa, Mari Yamamoto, Yaoko Takano, Chiyo K. Imamura, Yasutaka Chiba, Daisuke Takiguchi, Tutomu Ezumi, Toshimi Takano	2024	9
16	A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer Journal of Clinical Oncology ·Norio Kohno, K. Aogi, Hironobu Minami, Seigo Nakamura, T Asaga, Y Iino, Toru Watanabe, Carsten Goessl, Yasuo Ohashi, S. Takashima	2004	9
17	P1-12-19: Phase I Study of Single Agent Trastuzumab Emtansine in Japanese Patients with Human Epidermal Growth Factor Receptor2 (HER2)-Positive Metastatic Breast Cancer (JO22591). Cancer Research ·K. Aogi, Masashi Ando, Hiroji Iwata, Fumikata Hara, M. Matsubara, Yasuhiro Fujiwara	2011	8
18	Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer Annals of Oncology ·Toshiaki Saeki, Shinzaburo Noguchi, K. Aogi, Hideo Inaji, Toshio Tabei, Tadashi Ikeda	2009	4
19	Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial Journal of Clinical Oncology ·Toru Watanabe, Masaru Kuranami, Kenichi Inoue, N Masuda, K. Aogi, Hiroji Iwata, Hirofumi Mukai, Shin Tanaka, Takuhiro Yamaguchi, Yasuo Ohashi	2009	4
20	Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04) Cancer Research ·Shoichiro Ohtani, Norikazu Masuda, Y-H Im, S-A. Im, Byeong‐Woo Park, S-B. Kim, Y. Yanagita, Shintaro Takao, Shinji Ohno, K. Aogi, Hiroji Iwata, Katsuhide Yoshidome, Rieko Nishimura, Yasuo Ohashi, SJ Lee, Masakazu Toi	2013	3

About K. Aogi

K. Aogi is a scholar working on Cancer Research, Oncology, Dermatology, Biotechnology and Pathology and Forensic Medicine, having authored 33 papers that have together received 770 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (13 papers), Advanced Breast Cancer Therapies (6 papers), Chemotherapy-related skin toxicity (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Breast Lesions and Carcinomas (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (535 citations), Cancer Research (214 citations), Radiology, Nuclear Medicine and Imaging (185 citations), Genetics (52 citations) and Dermatology (40 citations). K. Aogi has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Hiroji Iwata, Shigemitsu Takashima, Norikazu Masuda, Yasuhiro Fujiwara, Yutaka Tokuda, Yosuke Sasaki, Yoshiaki Rai, Noriyuki Katsumata, Kan Yonemori and Steve Goodison. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancer Research, Japanese Journal of Clinical Oncology and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact